Get the Stockscreener App
3.6257
3.46%
-0.1343
Cytomx Therapeutics Inc stock is traded at $3.6257, with a volume of 1.74M.
It is down -3.46% in the last 24 hours and down -17.50% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$3.76
Open:
$3.75
24h Volume:
1.74M
Relative Volume:
0.27
Market Cap:
$789.17M
Revenue:
$76.20M
Net Income/Loss:
$-17.37M
P/E Ratio:
398.43
EPS:
0.0091
Net Cash Flow:
$-75.81M
1W Performance:
-0.27%
1M Performance:
-17.50%
6M Performance:
-13.98%
1Y Performance:
+62.78%
1-Day Range:
$3.57
$3.78
1-Week Range:
$3.57
$3.85
52-Week Range:
$1.72
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.625 | 818.56M | 76.20M | -17.37M | -75.81M | 0.0091 |
VRTX
Vertex Pharmaceuticals Inc
|
436.54 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.30 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.34 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX Therapeutics: Cashed Up With Catalysts Ahead (NASDAQ:CTMX) - Seeking Alpha
Wolfe Research Initiates Coverage of CytomX Therapeutics (CTMX) with Outperform - Insider Monkey
CytomX Therapeutics to Present at Upcoming June Investor Conferences - The Manila Times
CytomX Therapeutics in June investor events at Jefferies, Goldman Sachs - Stock Titan
CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Wolfe Research initiates CytomX stock with outperform rating By Investing.com - Investing.com Australia
Wolfe Research Initiates CytomX Therapeutics With Outperform Rating - Moomoo
Wolfe Research initiates CytomX stock with outperform rating - Investing.com
CytomX appoints Mamata Gokhale as regulatory affairs head By Investing.com - Investing.com Australia
CytomX appoints Mamata Gokhale as regulatory affairs head - Investing.com
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory ... - Caledonian Record
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs - Yahoo Finance
Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation - MSN
Seven Fleet group beneficially owns 1,085,398 CTMX shares (NASDAQ: CTMX) - Stock Titan
Longitude funds, managers report sizable CTMX stakes (CTMX) — 7.0% by principals - Stock Titan
Venrock group files Amendment reporting 9.98M CTMX shares (NASDAQ: CTMX) - Stock Titan
Kynam Capital (CTMX) discloses 15.0M-share, 6.90% stake in CytomX (Schedule 13G/A) - Stock Titan
Perceptive (CTMX) reports 10,098,824 shares, a 4.6% stake - Stock Titan
CytomX’s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor Radar - TipRanks
CytomX Therapeutics stock (US23284F1057): Recent price volatility draws attention - AD HOC NEWS
Brokers Are Upgrading Their Views On CytomX Therapeutics, Inc. (NASDAQ:CTMX) With These New Forecasts - 富途牛牛
HC Wainwright Analysts Increase Earnings Estimates for CTMX - MarketBeat
Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher - simplywall.st
New Forecasts: Here's What Analysts Think The Future Holds For CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Yahoo Finance
Earnings call transcript: CytomX Therapeutics Q1 2026 beats EPS forecast - Investing.com UK
Earnings call transcript: CytomX Therapeutics Q1 2026 beats EPS forecast By Investing.com - Investing.com Nigeria
CTMX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts CytomX stock price target on trial data By Investing.com - Investing.com South Africa
Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates - 富途牛牛
Earnings Beat: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
H.C. Wainwright cuts CytomX stock price target on trial data - Investing.com
CytomX Therapeutics: Early-Stage Pipeline, Trial Setbacks and High Risks on the Road to Profitability - TipRanks
CytomX Earnings Call Highlights Varseta-M Momentum - TipRanks
CytomX (CTMX) Q1 2026 Earnings Transcript - AOL.com
CytomX Q1 2026 slides: Varseta-M shows 32% response in CRC trial - Investing.com Canada
Earnings call transcript: CytomX Therapeutics beats Q1 2026 forecasts - Investing.com UK
CytomX Therapeutics (CTMX) Prepares for Transformational Year in 2026 - GuruFocus
Earnings call transcript: CytomX Therapeutics beats Q1 2026 forecasts By Investing.com - Investing.com India
CytomX Therapeutics (CTMX) reports Q1 loss, beats revenue estimates - MSN
CytomX Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CytomX Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) Q1 2026 Revenue Beat Sparks Cautious Market Rally - ChartMill
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
CytomX Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (CTMX) CytomX Therapeutics, Inc. Reports Q1 Revenue $10.3M, vs. FactSet Est of $4.7M - marketscreener.com
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytomx Therapeutics Inc Stock (CTMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CEO |
Mar 17 '26 |
Sale |
6.42 |
118,969 |
764,138 |
1,078,922 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Mar 17 '26 |
Sale |
6.42 |
31,492 |
202,273 |
300,760 |
| Ogden Christopher | Chief Financial Officer |
Mar 17 '26 |
Sale |
6.42 |
19,323 |
124,112 |
296,948 |
| McCarthy Sean A. | CEO |
Nov 06 '25 |
Sale |
4.54 |
101,793 |
461,906 |
987,891 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):